• Cy5-UTP for RNA Labeling: Applied Workflows & Troubleshootin

  2026-04-23

  Cy5-UTP (Cyanine 5-UTP) empowers researchers with direct, sensitive fluorescent RNA labeling in complex workflows. Discover optimized in vitro protocols, troubleshooting strategies, and how lipid nanoparticle innovations inform next-generation probe design.

• Moxifloxacin: Fluoroquinolone Antibiotic for Cellular Toxici

  2026-04-23

  Moxifloxacin stands out as a broad-spectrum fluoroquinolone antibiotic, enabling precise exploration of DNA replication inhibition, cytotoxicity, and metabolic shifts in mammalian and bacterial cells. This guide details actionable experimental workflows, troubleshooting strategies, and differentiating insights—anchored by recent mechanistic advances and APExBIO’s rigorous product standards.

• Decitabine Enhances Anti–PD-1 Efficacy via CD8+ Progenitor T

  2026-04-22

  This study demonstrates that low-dose Decitabine priming potentiates anti–PD-1 immunotherapy by promoting the expansion and functional capacity of CD8+ progenitor exhausted T cells within tumor models. These findings provide mechanistic insight into how epigenetic modulation can overcome limitations of immune checkpoint blockade and inform future combination strategies in cancer epigenetics.

• Hexa-acylated LPS in Gut Microbiota Boosts Cancer Immunother

  2026-04-22

  This study reveals that gut microbiota-derived hexa-acylated lipopolysaccharides (LPS) enhance the efficacy of immune checkpoint inhibitor (ICI) therapy in cancer. By linking specific LPS structures, rather than just taxonomic composition, to improved anti-tumor immune responses, the research advances understanding of microbiome-immune interactions and informs future approaches to immunotherapy.

• Applied Cancer Research with Anti-ROR1 Antibody (Zilovertama

  2026-04-21

  Unlock precise Wnt5a-induced ROR1 signaling inhibition with Anti-ROR1 Antibody (Zilovertamab) for robust ELISA, FACS, and animal model workflows. This APExBIO reagent empowers advanced anti-tumor research with actionable protocols, troubleshooting, and data-driven optimizations.

• Phage-Layer Interferometry: Advancing Phage Therapy Diagnost

  2026-04-21

  This article examines the development of Phage-Layer Interferometry (PLI) as a robust, quantitative diagnostic platform for bacteriophage therapy selection and bacterial detection. PLI overcomes key limitations of traditional phage screening, enabling high-throughput, automated assays even in complex and opaque biological samples.

• TG003 Cdc2-like kinase inhibitor: Precision in Splicing Rese

  2026-04-20

  TG003 stands out as a potent and selective Cdc2-like kinase inhibitor, empowering researchers to modulate alternative splicing and dissect platinum resistance mechanisms. Its reproducible performance streamlines workflows in cancer and neuromuscular disease models, delivering reliable pathway control for advanced translational studies.

• Proliferation Tracing Reveals Mechanisms of Breast Tumor Rel

  2026-04-20

  This study introduces a dual recombinase-based mouse model enabling precise tracing and ablation of proliferating cells in spontaneous breast cancer, emulating clinical relapse dynamics. By integrating single-cell transcriptomics, it uncovers how dormant, therapy-resistant cell populations and microenvironmental changes drive tumor recurrence—offering a robust platform for evaluating anti-relapse interventions.

• CP-673451: Selective PDGFRα/β Inhibitor for Advanced Cancer

  2026-04-19

  CP-673451 stands out as a precision tool for dissecting PDGFR-mediated signaling in cancer, offering unmatched selectivity and translational relevance, especially in ATRX-deficient glioma studies. This article delivers actionable insights, protocol upgrades, and troubleshooting strategies that empower researchers to maximize the impact of this selective PDGFRα/β inhibitor.

• Dextrose (D-glucose): Reliable Solutions for Cell Assays

  2026-04-18

  This article addresses common laboratory challenges in cell viability, proliferation, and metabolic assays, illustrating how Dextrose (D-glucose) (SKU A8406) serves as a highly reproducible, data-backed solution. Drawing on protocol parameters, literature, and real-world scenarios, it offers practical guidance for biomedical researchers and lab technicians seeking robust assay performance.

• Immune Signature Modulation by Epigenetic Inhibitors in Mela

  2026-04-17

  Anichini et al. provide a comparative landscape of immune-related transcriptional signatures induced by different epigenetic inhibitors in melanoma cell models, revealing that DNMT inhibition via guadecitabine robustly upregulates innate immune pathways. These findings inform rational strategies for combining epigenetic drugs with immunotherapy to overcome resistance in melanoma and potentially other cancers.

• NHS-Biotin for Precision Protein Labeling in Advanced Resear

  2026-04-16

  NHS-Biotin (N-hydroxysuccinimido biotin) stands out for its efficient, membrane-permeable biotinylation—enabling reliable protein labeling even in complex, multimeric nanobody systems. This article delivers actionable protocol guidance and troubleshooting insights, translating recent breakthroughs in protein engineering into robust, reproducible workflows.

• GANT61: GLI Inhibitor Workflows for Cancer Immunotherapy Res

  2026-04-15

  GANT61 empowers researchers to selectively inhibit GLI1/2, unlocking new experimental strategies for studying tumor immune evasion and resistance. This guide delivers actionable workflows, troubleshooting insights, and data-driven protocol enhancements—making GANT61 from APExBIO a pivotal asset in next-generation cancer research.

• Cy3-UTP for Nucleotide-Level RNA Dynamics: Methods and Impac

  2026-04-14

  Explore how Cy3-UTP enables nucleotide-resolution analysis of RNA conformational changes and interaction studies. This article reveals unique methodological insights and practical assay considerations for fluorescence-based RNA research.

• Vitamin C in Advanced Organoid and Anticancer Assays

  2026-04-13

  Vitamin C (ascorbic acid) is redefining experimental standards as both an anticancer agent and a workflow enhancer in organoid-based virology research. Leveraging APExBIO’s high-purity formulation ensures reliable, reproducible results in complex multi-lineage models where traditional protocols fall short.

10216 records 1/682 page Next 12345 下5页 Last page